{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T08:57:46Z","timestamp":1775897866197,"version":"3.50.1"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","funder":[{"DOI":"10.13039\/501100003032","name":"Association Nationale de la Recherche et de la Technologie","doi-asserted-by":"crossref","award":["2021\/1440"],"award-info":[{"award-number":["2021\/1440"]}],"id":[{"id":"10.13039\/501100003032","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,10]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Mycophenolic acid is widely used to treat lupus nephritis (LN). However, it exhibits complex pharmacokinetics with large interindividual variability. This study aimed to develop a population pharmacokinetic (popPK) model and a 3-sample limited sampling strategy (LSS) to optimize therapeutic drug monitoring in Indian patients with LN.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Five blood samples from each LN patient treated with mycophenolic acid were collected at steady-state predose and 1, 2, 4, and 6 hours postdose. Demographic parameters were tested as covariates to explain interindividual variability. PopPK analysis was performed using Monolix and the stochastic approximation expectation-maximization algorithm. An LSS was derived from 500 simulated pharmacokinetic (PK) profiles using maximum a posteriori Bayesian estimation to estimate individual PK parameters and area under the curve (AUC). The LSS-calculated AUC was compared with the AUC calculated using the trapezoidal rule and all the simulated samples.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>A total of 51 patients were included in this study. Based on the 245 mycophenolic acid concentrations, a 1-compartmental model with double absorption using gamma distributions best fitted the data. None of the covariates improved the model significantly. The model was internally validated using diagnostic plots, prediction-corrected visual predictive checks, and bootstrapping. The best LSS included samples at 1, 2, and 4 hours postdose and exhibited good performances in an external dataset (root mean squared error, 21.9%; mean bias, \u22124.20%).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>The popPK model developed in this study adequately estimated the PK of mycophenolic acid in adult Indian patients with LN. This simple LSS can optimize TDM based on the AUC in routine practice.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/ftd.0000000000001213","type":"journal-article","created":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T19:00:09Z","timestamp":1715281209000},"page":"567-574","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Population Pharmacokinetics and Limited Sampling Strategy of Mycophenolate Mofetil for Indian Patients With Lupus Nephritis"],"prefix":"10.1097","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2892-9204","authenticated-orcid":false,"given":"K\u00e9vin","family":"Koloskoff","sequence":"first","affiliation":[{"name":"Inserm, Pharmacology & Toxicology, U 1248, Limoges, France;"},{"name":"EXACTCURE, Nice, France;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ritika","family":"Panwar","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Post Graduate Institute of Medical Education and Research, Chandigarh, India;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manish","family":"Rathi","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Post Graduate Institute of Medical Education and Research, Chandigarh, India;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sumith","family":"Mathew","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology, Christian Medical College Vellore, Vellore, India;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aman","family":"Sharma","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Post Graduate Institute of Medical Education and Research, Chandigarh, India;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre","family":"Marquet","sequence":"additional","affiliation":[{"name":"Inserm, Pharmacology & Toxicology, U 1248, Limoges, France;"},{"name":"Pharmacology & Toxicology, University of Limoges, U 1248, Limoges, France; and"},{"name":"CHU Limoges, Service Pharmacologie, Toxicologie et Pharmacovigilance, Limoges, France."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sylvain","family":"Benito","sequence":"additional","affiliation":[{"name":"EXACTCURE, Nice, France;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1695-0695","authenticated-orcid":false,"given":"Jean-Baptiste","family":"Woillard","sequence":"additional","affiliation":[{"name":"Inserm, Pharmacology & Toxicology, U 1248, Limoges, France;"},{"name":"Pharmacology & Toxicology, University of Limoges, U 1248, Limoges, France; and"},{"name":"CHU Limoges, Service Pharmacologie, Toxicologie et Pharmacovigilance, Limoges, France."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5548-4685","authenticated-orcid":false,"given":"Smita","family":"Pattanaik","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Post Graduate Institute of Medical Education and Research, Chandigarh, India;"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2024,5,9]]},"reference":[{"key":"R1-20250603","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1056\/NEJMra1100359","article-title":"Systemic lupus erythematosus","volume":"365","author":"Tsokos","year":"2011","journal-title":"N Engl J Med"},{"key":"R2-20250603","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1136\/annrheumdis-2020-216924","article-title":"2019 update of the joint European League against rheumatism and European renal association-European Dialysis and transplant association (EULAR\/ERA-EDTA) recommendations for the management of lupus nephritis","volume":"79","author":"Fanouriakis","year":"2020","journal-title":"Ann Rheum Dis."},{"key":"R3-20250603","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1097\/FTD.0000000000000871","article-title":"Personalized therapy for mycophenolate: consensus report by the international association of therapeutic drug monitoring and clinical toxicology","volume":"43","author":"Bergan","year":"2021","journal-title":"Ther Drug Monit"},{"key":"R4-20250603","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1097\/FTD.0000000000000223","article-title":"Therapeutic drug monitoring of mycophenolic acid in lupus nephritis: a review of current literature","volume":"37","author":"\u0141uszczy\u0144ska","year":"2015","journal-title":"Ther Drug Monit"},{"key":"R5-20250603","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1111\/bcp.12678","article-title":"Exposure\u2013effect relationship of mycophenolic acid and prednisolone in adult patients with lupus nephritis","volume":"80","author":"Abd Rahman","year":"2015","journal-title":"Br J Clin Pharmacol"},{"key":"R6-20250603","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s00467-020-04733-x","article-title":"Mycophenolic acid area under the concentration-time curve is associated with therapeutic response in childhood-onset lupus nephritis","volume":"36","author":"Godron-Dubrasquet","year":"2021","journal-title":"Pediatr Nephrol (Berlin, Germany)"},{"key":"R7-20250603","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1007\/s40262-017-0593-6","article-title":"Population pharmacokinetics of mycophenolic acid: an update","volume":"57","author":"Kiang","year":"2018","journal-title":"Clin Pharmacokinet"},{"key":"R8-20250603","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1007\/s40262-018-0687-9","article-title":"Comment on \u201cpopulation pharmacokinetics of mycophenolic acid: an update.\u201d","volume":"57","author":"Woillard","year":"2018","journal-title":"Clin Pharmacokinet"},{"key":"R9-20250603","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1177\/0961203320931567","article-title":"Population pharmacokinetics of mycophenolic acid in Mexican patients with lupus nephritis","volume":"29","author":"Romano-Aguilar","year":"2020","journal-title":"Lupus"},{"key":"R10-20250603","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1007\/s13318-017-0420-3","article-title":"Development of improved dosing regimens for mycophenolate mofetil based on population pharmacokinetic analyses in adults with lupus nephritis","volume":"42","author":"Abd Rahman","year":"2017","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"R11-20250603","doi-asserted-by":"crossref","first-page":"837","DOI":"10.2165\/00003088-200544080-00005","article-title":"A double absorption-phase model adequately describes mycophenolic acid plasma profiles in de novo renal transplant recipients given oral mycophenolate mofetil","volume":"44","author":"Pr\u00e9maud","year":"2005","journal-title":"Clin Pharmacokinet"},{"key":"R12-20250603","doi-asserted-by":"crossref","first-page":"667","DOI":"10.2165\/11317140-000000000-00000","article-title":"Pharmacokinetic modelling and development of Bayesian estimators for therapeutic drug monitoring of mycophenolate mofetil in reduced-intensity haematopoietic stem cell transplantation","volume":"48","author":"Saint-Marcoux","year":"2009","journal-title":"Clin Pharmacokinet"},{"key":"R13-20250603","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.phrs.2011.01.009","article-title":"Development of a Bayesian estimator for the therapeutic drug monitoring of mycophenolate mofetil in children with idiopathic nephrotic syndrome","volume":"63","author":"Saint-Marcoux","year":"2011","journal-title":"Pharmacol Res"},{"key":"R14-20250603","doi-asserted-by":"crossref","first-page":"277","DOI":"10.2165\/00003088-200847040-00005","article-title":"Pharmacokinetic study of mycophenolate mofetil in patients with systemic lupus erythematosus and design of Bayesian estimator using limited sampling strategies","volume":"47","author":"Zahr","year":"2008","journal-title":"Clin Pharmacokinet"},{"key":"R15-20250603","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s00228-023-03587-0","article-title":"Limited sampling strategy and population pharmacokinetic model of mycophenolic acid in pediatric patients with systemic lupus erythematosus: application of a double gamma absorption model with SAEM algorithm","volume":"80","author":"Koloskoff","year":"2024","journal-title":"Eur J Clin Pharmacol"},{"key":"R16-20250603","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/10601339509079574","article-title":"Review of methods in population pharmacokinetics","volume":"12","author":"Carter","year":"1995","journal-title":"Clin Res Regul Aff"},{"key":"R17-20250603","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1093\/rheumatology\/kep346","article-title":"Influence of race\/ethnicity on response to lupus nephritis treatment: the ALMS study","volume":"49","author":"Isenberg","year":"2010","journal-title":"Rheumatology (Oxford, England)"},{"key":"R18-20250603","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1097\/FTD.0b013e3181cd550f","article-title":"A reliable limited sampling strategy for the estimation of mycophenolic acid area under the concentration time curve in adult renal transplant patients in the stable posttransplant period","volume":"32","author":"Mathew","year":"2010","journal-title":"Ther Drug Monit"},{"key":"R19-20250603","doi-asserted-by":"crossref","first-page":"408","DOI":"10.4103\/0971-4065.174242","article-title":"Development and validation of limited sampling strategy equation for mycophenolate mofetil in children with systemic lupus erythematosus","volume":"26","author":"Prabha","year":"2016","journal-title":"Indian J Nephrol"},{"key":"R20-20250603","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1111\/j.1523-1755.2004.00443.x","article-title":"The classification of glomerulonephritis in systemic lupus erythematosus revisited","volume":"65","author":"Weening","year":"2004","journal-title":"Kidney Int"},{"key":"R21-20250603","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1080\/00365513.2016.1230775","article-title":"Simultaneous determination of mycophenolate and its metabolite mycophenolate-7-o-glucuronide with an isocratic HPLC-UV-based method in human plasma and stability evaluation","volume":"76","author":"Rissling","year":"2016","journal-title":"Scand J Clin Lab Invest"},{"key":"R23-20250603","doi-asserted-by":"crossref","first-page":"2979","DOI":"10.1007\/s11095-016-2020-3","article-title":"Enhanced method for diagnosing pharmacometric models: random sampling from conditional distributions","volume":"33","author":"Lavielle","year":"2016","journal-title":"Pharm Res"},{"key":"R24-20250603","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.phrs.2015.07.012","article-title":"Mycophenolic mofetil optimized pharmacokinetic modelling, and exposure-effect associations in adult heart transplant recipients","volume":"99","author":"Woillard","year":"2015","journal-title":"Pharmacol Res"},{"key":"R25-20250603","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1097\/01.ftd.0000162231.90811.38","article-title":"Maximum a posteriori bayesian estimation of mycophenolic acid pharmacokinetics in renal transplant recipients at different postgrafting periods","volume":"27","author":"Pr\u00e9maud","year":"2005","journal-title":"Ther Drug Monit"},{"key":"R26-20250603","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1111\/j.1365-2125.2010.03615.x","article-title":"Population pharmacokinetics and Bayesian estimator of mycophenolic acid in children with idiopathic nephrotic syndrome","volume":"69","author":"Zhao","year":"2010","journal-title":"Br J Clin Pharmacol"},{"key":"R27-20250603","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1111\/j.1365-2125.2012.04213.x","article-title":"Population pharmacokinetics of mycophenolic acid and dose optimization with limited sampling strategy in liver transplant children","volume":"74","author":"Barau","year":"2012","journal-title":"Br J Clin Pharmacol"},{"key":"R28-20250603","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1111\/bcp.12392","article-title":"Pharmacokinetics of mycophenolate mofetil in children with lupus and clinical findings in favour of therapeutic drug monitoring","volume":"78","author":"Woillard","year":"2014","journal-title":"Br J Clin Pharmacol"},{"key":"R29-20250603","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1111\/bcp.14261","article-title":"Population pharmacokinetics and Bayesian estimators for intravenous mycophenolate mofetil in haematopoietic stem cell transplant patients","volume":"86","author":"Labriffe","year":"2020","journal-title":"Br J Clin Pharmacol"},{"key":"R30-20250603","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1007\/s40262-020-00959-y","article-title":"Clinical pharmacokinetics and bayesian estimators for the individual dose adjustment of a generic formulation of tacrolimus in adult kidney transplant recipients","volume":"60","author":"Marquet","year":"2021","journal-title":"Clin Pharmacokinet"},{"key":"R31-20250603","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1002\/cpt1979263294","article-title":"Forecasting individual pharmacokinetics","volume":"26","author":"Sheiner","year":"1979","journal-title":"Clin Pharmacol Ther"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001213","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T17:10:38Z","timestamp":1748970638000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001213"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,9]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000001213","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5,9]]},"assertion":[{"value":"2023-11-22","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-03-04","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}